New drug combo shows promise for Hard-to-Treat cancers
NCT ID NCT05199753
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested an experimental drug called LM-108, alone or combined with another immunotherapy, in 78 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looked for early signs that the drug might shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LM-108 (an experimental drug) and an anti-PD-1 antibody (a type of immunotherapy)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early, first-in-human trial with only 78 participants, so the main goal is safety, not effectiveness. The drug may not shrink tumors or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alfred Hospital
Melbourne, Victoria, VIC 3004, Australia
-
Blacktown Hospital
Sydney, New South Wales, NSW 2148, Australia
-
Cabrini Health Limited
Malvern, Victoria, VIC 3144, Australia
-
ICON Cancer Centre
South Brisbane, Queensland, QLD 4101, Australia
-
One Clinical Research Pty Ltd.
Nedlands, Western Australia, WA 6009, Australia
-
Sunshine Coast University Private Hospital
Birtinya, Queensland, QLD 4575, Australia